Mereo acquired a portfolio of three product candidates from Novartis in July 2015 including BPS-804 (setrusumab), BCT-197 (acumapimod), and BGS-649 (leflutrozole).
The company in-licensed MPH-966 (alvelestat) from AstraZeneca in October 2017.
Mereo has a strategic collaboration with Celgene Corporation around the OMP-313M32 (etigilimab) program following its merger with OncoMed. The collaboration includes a significant option exercise payment if exercised and payments for achievement of development, regulatory and commercial milestones and royalty payments based on future product sales.